Clinical Trial Update: Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study of MLN0128 (sapanisertib) in combination with paclitaxel, with/without trastuzumab, in subjects with advanced solid malignancies a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies
• Solid Malignancies

Drugs mentioned

• MLN0128 (sapanisertib)
• PACLITAXEL (PACLITAXEL)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Advanced Solid Malignancies, Hematologic Malignancies | Phase 1 | Status: COMPLETED | Results posted: 2019-08-08